乌司他丁治疗合并凝血功能障碍的危重症患者临床效果评价

Evaluation of the clinical effect of ulinastatin in the treatment of critically ill patients with coagulation dysfunction

目的分析乌司他丁治疗合并凝血功能障碍的危重症患者临床效果。方法选取2017年3月~2020年3月合并凝血功能障碍的危重症患者82例,其中41例给予常规治疗为对照组,另41例在对照组基础上联合乌司他丁为试验组,比较两组治疗前后凝血功能[活化部分凝血酶原时间(APTT)、凝血酶原时间(PT)、D-二聚体、血小板计数(PLT)]、病情程度(DIC评分、APACHEⅡ评分)。结果治疗后试验组APTT、PT较对照组短,D-二聚体水平较对照组低,PLT水平较对照组高(P<0.05);治疗后两组DIC评分、APACHEⅡ评分均有所降低,且试验组低于对照组(P<0.05)。结论乌司他丁治疗合并凝血功能障碍的危重症患者具有较高价值,可有效改善凝血功能,降低病情程度。

Objective To analyze the clinical effect of ulinastatin on critically ill patients with coagulation dysfunction.Methods A total of 82 critically ill patients with coagulation dysfunction were selected from our hospital from March 2017 to March 2020,of which 41 cases were given conventional treatment as the control group,and the other 41 cases were combined with ulinastatin on the basis of the control group as the test group.Comparing the coagulation function[activated partial prothrombin time(APTT),prothrombin time(PT),D-dimer,platelet count(PLT)]and disease severity(DIC score,APACHEⅡscore)before and after treatment between the 2 groups.Results After treatment,the APTT and PT of the test group were shorter than that of the control group,the level of D-dimer was lower than that of the control group,and the level of PLT was higher than that of the control group(P<0.05);after treatment,the DIC score and APACHEⅡscore of both groups decreased,and the test group was lower than the control group(P<0.05).Conclusion Ulinastatin has high value in the treatment of critically ill patients with coagulation dysfunction,which can effectively improve coagulation function and reduce the degree of illness.